Kymera reports Q1 net loss of $40.9M, cash $516M; initiates MDM2 degrader trial

Kymera Therapeutics, Inc.

2023-Q1 EPS reported -$0.70 revenue$9,466,000

Net loss $40.9M vs $36.7M Q1 2022; R&D expenses $42.2M (up from $35.9M).
Cash and investments $516M as of March 31, 2023; runway into H2 2025.
Phase 1 trial of MDM2 degrader KT-253 initiated in relapsed/refractory myeloid malignancies and solid tumors.
KT-474 (IRAK4 degrader) Phase 2 planned in hidradenitis suppurativa for 2023; Phase 1 data at EADV May 18.
KT-333 and KT-413 Phase 1 updates at ICML in June; anti-tumor activity data expected later in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kymera Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 4, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.